L3VLUP
ProSign in

SUPN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SUPNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SUPN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterSUPNLLY
Q3 20203 holders, $49m33 holders, $14.1bn
Q4 20201 holders, $47m29 holders, $17.3bn
Q1 20211 holders, $46m24 holders, $23.0bn
Q2 20212 holders, $48m24 holders, $27.8bn
Q3 20213 holders, $40m31 holders, $29.9bn
Q4 20212 holders, $36m31 holders, $34.7bn
Q1 20224 holders, $62m24 holders, $35.3bn
Q2 20224 holders, $62m33 holders, $42.7bn
Q3 20225 holders, $75m31 holders, $43.4bn
Q4 20225 holders, $53m31 holders, $46.6bn
Q1 20233 holders, $55m33 holders, $44.3bn
Q2 20232 holders, $45m37 holders, $59.6bn
Q3 20231 holders, $40m44 holders, $67.6bn
Q4 20231 holders, $40m45 holders, $73.6bn
Q1 20243 holders, $91m41 holders, $95.3bn
Q2 20241 holders, $45m43 holders, $110bn
Q3 20243 holders, $61m45 holders, $107bn
Q4 20243 holders, $75m46 holders, $93.9bn
Q1 20253 holders, $54m42 holders, $98.4bn
Q2 20253 holders, $80m43 holders, $93.2bn
Q3 20256 holders, $244m39 holders, $86.7bn
Q4 20259 holders, $381m41 holders, $123bn
Q1 20268 holders, $399m39 holders, $106bn
Q2 20266 holders, $299m44 holders, $132bn
SUPN

Supernus Pharmaceuticals Inc

Holders
1
Reported value
$40m
Buyers
0
Sellers
1

Breadth -1 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$73.6bn
Buyers
27
Sellers
21

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SUPN (0)

None.

Only LLY (44)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, and 19 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →